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ABSTRAK
Aneusomi merupakan perubahan genetik awal dan suatu ciri utama dalam 
kebanyakan tumor pejal. Penemuan aneusomi biasanya dikaitkan dengan pesakit 
kanser dengan prognosis buruk. Penglibatan penyusunan semula gen PAX8-PPARγ 
dalam tumorigenesis lesi tiroid folikular telah dikaji. Namun begitu, tidak banyak 
laporan yang melaporkan kehadiran aneusomi gen PPARγ pada lokus 3p25 pada 
lesi tiroid folikular. Samada kehadiran keabnormalan ini dapat meningkatkan 
diagnosis, pengkelasan atau prognosis masih tidak dapat ditentukan. Kajian ini 
melaporkan penemuan aneusomi dalam tiga lesi tiroid folikular [dua karsinoma 
tiroid folikular (FTC) dan satu kes adenoma sel Hurthle (HCA)] yang menunjukkan 
kehadiran aneusomi 3p25 menerusi teknik penghibridan in-situ berpendaflur (FISH). 
Trisomi 3p25 telah ditemui pada satu kes FTC dan satu kes HCA manakala satu kes 
FTC menunjukkan tetrasomi 3p25. Lesi sel Hurthle berbeza dari segi klinikal dan 
histologikal daripada neoplasma folikular yang lain. Namun, penemuan aneusomi 
dalam HCA dan FTC menunjukkan kewujudan pertalian biologi di antara neoplasma 
sel Hurthle dan folikular. Di samping berkongsi ciri-ciri histologi dengan neoplasma 
tiroid konvensional, neoplasma sel Hurthle mungkin berkongsi perubahan genetik 
yang sama di peringkat awal pembentukan tumor folikular.
Kata kunci: aneusomi 3p25, PPARγ, karsinoma tiroid folikular, karsinoma sel Hurthle, 
penghibridan in-situ berpendaflur
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ABSTRACT
Aneusomy is an early genetic event and a characteristic feature of many solid tumors. 
It is often associated with poor prognosis in cancer patients. The involvement of 
PAX8-PPARγ rearrangement in tumorigenesis of follicular thyroid lesions has been 
widely assessed. However, there were few reports on aneusomy of the PPARγ gene 
at the 3p25 locus in follicular thyroid lesions. It remains undetermined whether 
these abnormalities can be translated into improved diagnosis, classification, or 
outcome prediction. Herein, we report three cases of follicular thyroid neoplasms 
[two follicular thyroid carcinomas (FTCs) and one Hurthle cell adenoma (HCA)] with 
3p25 aneusomy detected by fluorescence in situ hybridization (FISH). 3p25 trisomy 
was observed in one FTC and one HCA while 3p25 tetrasomy was observed in one 
FTC. Furthermore, all three lesions did not show overexpression of PPARγ protein. 
Hurthle cell neoplasms (HCN) are distinct clinically and histologically from other 
follicular thyroid neoplasms (FTN). However, the presence of the aneusomy in HCA 
and FTC indicates that there could be a biological continuum between the two and 
chromosomal gains might play an important role in the pathogenesis of these two 
types of neoplasms. Despite their differences, HCN and FTN may share the same 
early genetic event in tumour development.
Key words: 3p25 aneusomy, PPARγ, follicular thyroid carcinoma, Hurthle cell 
adenoma, fluorescence in-situ hybridization
BACKGROUND
Aneuploidy is one of the most frequent 
genetic abnormalities found in cancer 
(French et al. 2003; Pihan & Doxsey 
2003; Upender et al. 2003; Jonsson et 
al. 2008; Espadinha et al. 2009). It was 
known to be the cause of cancer over 
a century ago, based on Hansemann’s 
observations of asymmetric mitoses 
in epithelial cancers (Hansemann 
1890), which was further proven in 
1964, when Boveri showed evidence 
that aneuploidy in developing sea 
urchin embryos generates abnormal 
phenotypes (Boveri 1964). 
 Aneuploidy, resulting from full or 
partial aneusomies in which the copy 
number of entire chromosomes or 
chromosomal subregions is altered, 
has been proposed to be an early and 
genetically destabilizing force in cancer 
development (French et al. 2003). 
Increasing aneuploidy is associated with 
cancer progression and considered as a 
sign of malignancy, but the molecular 
mechanisms involved in aneuploidy 
in cancer remains undefined in the 
majority of human cancers, particularly 
in thyroid cancer (French et al. 2003; 
Banito et al. 2007). 
 The distribution of aneuploid cells 
within tumour cells is not uniform, 
indicating that thyroid cancers may 
be clonally heterogeneous, which is 
consistent with the notion that thyroid 
cancer cells may have chromosomal 
instability (Ouyang et al. 2002). Possibly 
due to the varying chromosome 
49
3p25 aneusomy in follicular thyroid neoplasms Med & Health 2012; 7(1): 47-56
composition, aneuploid cancer cells 
usually exhibit a wide spectrum of 
clinical aggressiveness (Isaka et al. 2003). 
These aneuploid cells could continue 
to segregate asymmetrically every time 
they divide in the “chromosome error 
propagation” process (Carlson et al. 
2000). This may explain the association 
of aneuploid cells in cancer patients with 
poor prognosis (Ouyang et al. 2002; 
Barril et al. 2000). There are reports 
suggesting that follicular carcinomas 
without PPARγ protein overexpression 
are more prone to develop distant 
metastasis, to invade locally, to present 
with poorly differentiated areas and 
to persist after surgery, suggesting 
an association between PPARγ 
protein underexpression with a less 
differentiated phenotype (Espadinha et 
al. 2009; Marques et al. 2004). 
 Previous studies on thyroid 
neoplasms reported common 
aneusomy of chromosome 3, 7, 10, 
12 and 17 (Barril et al. 2000; Criado et 
al. 1995; Belge et al. 1998). Aneusomy 
of chromosome 7 was also reported 
in bladder (Wolman et al. 2007) and 
prostate cancer (Alcaraz et al. 1994), 
while aneusomy of chromosome 
17 was reported in squamous cell 
carcinoma of the vulva (Carlson et al. 
2000), carcinoma of the breast (Wang 
et al. 2002) and lung (Nakamura et al. 
2003). French and co-workers reported 
3p25 aneusomy in 29% follicular 
carcinoma of the thyroid (French et al. 
2003). The 3p25 region is associated 
with PPARγ gene, which was widely 
investigated for its involvement with 
PAX8 gene in differentiating follicular 
thyroid carcinoma (FTC) from its 
benign counterpart (French et al. 2003; 
Marques et al. 2004; Kroll et al. 2000; 
Nikiforova et al. 2002; Dwight et al. 
2003; Nikiforova et al. 2003; Cheung 
et al. 2003; Hibi et al. 2004; Lui et al. 
2004; Sahin et al. 2005; Nikiforov 2010; 
Chia et al. 2010).
 Although rare in papillary thyroid 
carcinomas (PTCs), aneuploidy is a 
common feature of follicular thyroid 
adenomas (FTAs) and carcinomas 
(FTCs) (Espadinha et al. 2009; Banito 
et al. 2007; Ouyang et al. 2002). 
Aneuploidy is observed in about 
57% FTCs, 10-25% FTAs and 10-22% 
multinodular hyperplasia (Espadinha et 
al. 2009; Banito et al. 2007). Besides 
FTAs and FTCs, one study reported that 
aneuploidy was also detected in a subset 
of FTC that shows oncocytic features 
(Dettori et al. 2003). Some studies have 
reported that there is a tendency of an 
increased aneuploidy rate, generally 
from follicular adenomas to follicular 
carcinomas and from minimally invasive 
to widely invasive follicular carcinomas 
(Grant et al. 1990; Oyama et al. 1994). 
 World Health Organization (WHO) 
has categorized Hurthle cell neoplasms 
(HCN) as a variant of follicular 
neoplasms, as both neoplasms possess 
distinct features (Kroll 2004). Among 
the distinct features that differentiate 
the HCNs from FTN are the abnormal 
accumulation of mitochondria in the 
cytoplasm (Tallini et al. 1999), distinct 
morphologic features (Kroll 2004), 
frequent resistance to radio-iodine 
therapy (Stojadinovic et al. 2002), 
frequently detected RET rearrangements 
(Chiappetta et al. 2002) and lack of RAS 
mutations and PPARγ rearrangements 
in HCN (Nikiforova et al. 2003). 
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 In this paper, we present three cases 
of follicular thyroid neoplasms (two FTC 
and one HCA) with 3p25 aneusomy 
detected by FISH analysis without 




A 30 year-old lady presented to the 
surgery clinic of Universiti Kebangsaan 
Malaysia Medical Centre (UKMMC) 
with a right thyroid swelling. Fine-
needle aspiration cytology (FNAC) 
yielded cellular smears comprising 
of thyroid epithelial cells arranged in 
sheets and follicular pattern. The cells 
show generally round nuclei with 
scanty inspissated colloid. The overall 
features were reported as consistent 
with a follicular neoplasm. Total 
thyroidectomy was performed.
 Sections from the mass showed a 
partially encapsulated tumor consisting 
of neoplastic cells arranged in solid 
sheets as well as follicular pattern. 
Collections of inspissated colloid with 
multifocal areas of haemorrhage and 
necrosis were also present within the 
tumor. Generally, the cells display 
uniform round to oval nuclei with evenly 
distributed chromatin. Few mitotic 
figures were evident. A focal area of 
minimal capsular invasion was noted. 
However, presence of vascular invasion 
was not seen. There was no evidence 
of malignancy in the left thyroid gland 
and the isthmus. A diagnosis of FTC 
(minimally invasive) was made.
Case 2 (FC-19)
A 60 year-old lady presented to the 
surgery clinic, Putrajaya Hospital with 
a left thyroid swelling. FNA showed 
cellular smears comprising of neoplastic 
epithelial cells arranged in microfollicles 
with scanty to no colloid. Neoplastic 
cells display nuclear crowding and 
overlapping. A cytological diagnosis of 
follicular neoplasm was made. 
 Total thyroidectomy was performed. 
Sections from the right lobe and 
isthmus showed thyroid follicles of 
varying sizes intersected in areas by 
fibrous septae. Some of the thyroid 
follicles appeared dilated. There were 
areas of haemorrhage and oedema in 
the intervening stroma. Aggregates of 
foam cells were also present. 
 Sections from the left thyroid lobe 
showed tumour composed of closely 
packed follicles and trabeculae. 
The tumour cells were cuboidal 
with hyperchromatic nuclei. Areas 
of calcification and haemorrhage 
were noted but mitotic activity was 
inconspicuous. In some areas, capsular 
invasions were seen but no vascular 
invasion was present. A diagnosis of 
FTC was made.
Case 3 (FA-18)
A 29 year-old man presented to the 
surgery clinic, UKMMC with a well-
defined neck mass which moved with 
swallowing. The mass measured 3cm 
in diameter. 
 FNAC yielded scanty material. 
Smears showed a few thyroid epithelial 
cells arranged in microfollicles as well 
as singly dispersed cells displaying 
abundant granular cytoplasm with mild 
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anisonucleosis. Cytological features 
were reported as suspicious of a 
follicular neoplasm, Hurtle Cell type. 
 The excised specimen consists of 
two nodular lesions, each measuring 
3.5 x 2 x 1.5 cm and 1 x 1.1 x 1.5 cm. 
The larger nodule revealed a partially 
encapsulated mass composed of small 
colloid filled follicles lined by cells with 
abundant eosinophilic cytoplasm with 
mild nuclear pleomorphism. Some of 
the cells showed a trabecular pattern 
of arrangement. Sections from the 
smaller nodule showed variable sized 
colloid filled follicles lined by cuboidal 
epithelium. The nodules were separated 
by fibrous bands. No capsular invasion 
was seen. 
 A histological diagnosis of follicular 
adenoma of the thyroid (Hurthle cell 
type) was made. 
Cytogenetic Findings
FISH analysis was performed on the 
three follicular thyroid neoplasms, i.e. 
one HCA and two FTCs. Briefly, 3μm 
thick formalin-fixed paraffin-embedded 
(FFPE) tissue sections were cut from 
each of the cases. The sections were 
deparaffinised in 1× SkipDewax (Insitus 
Biotechnologies, New Mexico, USA) at 
80oC for 30 minutes and digested with 
1.5mg/ml pepsin (Sigma-Aldrich Co., 
St. Louis, USA) at 37°C for 1 hour. The 
FFPE tissue sections were hybridized 
with an in-house PAX8 (green)/ 
PPARγ (orange) dual colour extra-
signal bacterial artificial chromosome-
fluorescence in-situ hybridization 
(BAC-FISH) fusion probe assay 
(Chia et al. 2010) overnight at 37°C. 
After hybridization, the slides were 
washed, counterstained, analysed and 
documented using an epifluorescence 
microscope system (Applied Spectral 
Imaging System, Germany). Normal 
nuclei showed a two orange and two 
green signal pattern.
 3p25 aneusomy was detected in all 
three follicular thyroid neoplasms. Three 
orange and two green signal pattern was 
seen in the trisomy nuclei of one of the 
FTCs (FC-03). The other case of FTC (FC-
19) and the HCA (FA-18) showed four 
orange and two green signal patterns, 
indicating 3p25 tetrasomy (Figure 1). 
All three cases displayed the respective 
signal patterns in more than 50% of the 
200 nuclei analysed. No PAX8/PPARγ 
translocation was observed.
Immunohistochemical Findings
Immunohistochemistry was performed 
on FFPE tissue sections of all three 
follicular neoplasms using the 
monoclonal antibody PPARγ (Santa 
Cruz Biotechnology, Santa Cruz, CA). 
Antigen retrieval was performed in 
10mM citrate buffer (pH 9.9) at 95°C for 
40 minutes before incubating the slides 
with primary antibody (1:30) for 30 
minutes. The slides were then incubated 
with secondary antibody (ChemMate 
Dako Envision, HRP rabbit/mouse 
secondary antibody) and stained with 
DAB chromogen (DAKO) according 
to the manufacturer’s instruction. No 
PPARγ overexpression was detected in 
all three follicular thyroid neoplasms, 
i.e. two FTCs and one HCA. 
DISCUSSION 
In this paper, we report three cases of 
3p25 aneusomy associated with low 
PPARγ protein expression in a Hurthle 
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cell adenoma and two follicular 
carcinomas of the thyroid. It would 
be interesting to see whether similar 
findings have been reported by other 
authors, as these observations were 
seen in both benign and malignant 
lesions of two different entities of 
follicular thyroid neoplasms. 
 Aneusomy is often associated with 
a poor prognosis in cancer patients 
(Barril et al. 2000) and is considered as 
an adverse factor in thyroid carcinoma, 
although the cause of it remained 
undefined (Banito et al. 2007). Based 
on the study by Marques et al. (2004), 
clinically aggressive tumours had lower 
PPARγ protein expression than less 
aggressive carcinomas (Marques et al. 
2004). This is further supported by the 
fact that trisomies 7 and 12 in PTCs 
(which are rarely aneuploid) and FTCs 
showed a poor clinical outcome (Barril 
et al. 2000). There are also reports on 
the association between polysomy 
(aneusomy or aneuploidy) and high-
grade or late stage cancers (Placer et al. 
2005; Panani et al. 2004). 
 Although there were studies 
suggesting that aneuploidy was 
associated with genetic instability of 
many cancers (Banito et al. 2007; Barril 
et al. 2000; Wolman et al. 2007), it is 
still not clear why aneuploidy is such 
a highly variable prognostic marker for 
different tumours. Lengauer et al. (1998) 
reported that aneuploidy may not 
necessarily present with chromosomal 
instability (Lengauer et al. 1998). While 
chromosome losses or gains during 
cell division may trigger apoptosis 
in normal cells, tumour cells may be 
protected from apoptosis through 
a pre-existing mutation (Ouyang et 
al. 2002). Along this process, the 
rate of acquisition of chromosomal 
changes may be normal, and thus 
aneuploidy develops in the absence 
of chromosomal instability (Ouyang 
Figure 1: Interphase FISH analysis of (a) FTC 
(FC-03) showing trisomy nuclei with three 
orange and two green signal pattern; (b) 
FTC (FC-19) showing a tetrasomy nucleus 
with four orange and two green signal 
pattern; and (c) FTA (Hurthle cell type, 
FA-18) showing tetrasomy nuclei with four 
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et al. 2002). Meanwhile, Isaka and co-
workers (2003) postulated that the wide 
spectrum of clinical aggressiveness 
among different aneuploid cancers 
is due to the existence of different 
types of cancer aneuploidy created 
by various molecular defects in gene 
networks governing the cell cycle, 
recombination, the repair of double-
stranded deoxyribonucleic acid (DNA) 
breaks and the mitotic checkpoints 
(Isaka et al. 2003).
 None of the three follicular thyroid 
neoplasms analysed using the in-house 
PAX8 (green)/ PPARγ (orange) dual 
color extra-signal BAC-FISH fusion 
probe assay (Chia et al. 2010) had both 
3p25 aneusomy and PAX8/PPARγ 
rearrangement, which indicates the 
involvement of separate independent 
genetic pathways in early follicular 
thyroid tumorigenesis. French et al. 
(2003) suggested either the PAX8/PPARγ 
rearrangement or 3p25 aneuploidy can 
occur in early follicular carcinomas 
(French et al. 2003), which is similar to 
the detection of either RAS mutation or 
PPARγ rearrangement in FTCs (Tallini et 
al. 1998; Koenig 2010) as well as the 
detection of either RET rearrangements 
or NTRK1 rearrangement in PTCs 
(Pierotti  2001). 
 Previous cytogenetic studies have 
reported a high prevalence of trisomies 
and tetraploidies in FTN (Belge et al. 
1998; Hemmer et al. 1998; Roque et 
al. 1999). We observed presence of 
aneuploidy in all three cases, both 
benign and malignant follicular lesions, 
which is comparable with other 
previous reports (Banito et al. 2007; 
Barril et al. 2000; Hemmer et al. 1998; 
Johannessen et al. 1982). The presence 
of 3p25 aneusomy in both follicular 
adenoma and carcinoma of the 
thyroid support a stepwise adenoma 
to carcinoma sequence, or indicate 
the presence of carcinoma in situ. 
The appearance of 3p25 aneusomy in 
a HCA reported in this paper further 
suggests that gain of the 3p25 region 
is an early event in the development of 
follicular thyroid neoplasms. 
 In conclusion, the presence of the 
aneusomy in both cases of HCA and 
FTC indicates that there could be a 
biological continuum between the 
two neoplasms, and chromosomal 
gains might play an important role in 
the pathogenesis of these two types of 
neoplasms (Chia et al. 2010). Although 
there has been considerable speculation 
as to whether Hurthle cell tumours may 
be clinically and histologically distinct 
from other follicular thyroid neoplasms, 
the detection of 3p25 aneusomy in the 
case of HCA alongside with two FTCs 
suggests that Hurthle cell neoplasms 
may be considered a separate follicular 
thyroid tumour entity but shared 
the same genetic abnormality in the 
development of follicular thyroid 
tumour.
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